surrogate end point in heart failure patients, that's the reason why your paper deserves attention. According to this perspective please clarify if different selection criteria are needed (for example ejection fraction, vitamin D threshold, PTH threshold….) or if different vitamin D dosages would be superior, or if more echocardiographic parameter needs to be evaluated…
REVIEWER
Melaine Priscila Fidélix School of Pharmaceutical Science, São Paulo State University-UNESP, Araraquara, SP, Brazil REVIEW RETURNED 03-Jan-2018
GENERAL COMMENTS
It could be a little more discussed the plasma concentrations of vitamin D considered safe, so it would be easier to discuss which value to use for supplementation.
REVIEWER

Jason Oke University of Oxford, United Kingdom
REVIEW RETURNED
26-Jan-2018
GENERAL COMMENTS
The authors present a good systematic review with a clearly formulated research question. The analyses presented are appropriate and the conclusions drawn from the results are contrasted with the other literature around Vit d supplementation.
There a tendency towards hyperbole (e.g. "Subgroup analysis also revealed a remarkably lowered LVEDD in adults" but in general, the conclusions are balanced.
General criticisms.
The authors have made a good but not exhaustive search of the literature. For example, there has been no hand searching of journals and searching for unpublished literature. The locating of one or two extras studies can be crucial with a fairly small review.
Search strategy (in terms of words) seems appropriate but a content specialist may be a better judge of whether any important terms have been missed. Can they confirm a HF specialist has reviewed this?
I think the authors could do more to explain whether a 2.31mm decrease in LVEDD equates to patient benefit. i.e. I think this is particularly important as vit D supplementation doesn't seem to improve more obvious HF outcomes such as LVEF or more patientorientated outcomes like exercise tolerance (according to the Jiang review). What will this mean for HF patients their short or long-term outcomes.
I don't think this will be missed by the editorial review but the quality of English in this paper is not high. E.g.
"Make a retrieval of PubMed, EMbase, CNKI, Cochrane library and WEB SCINENCE"
"the main factor leading to economic loss due to its characterized by bad prognosis" In their defence, English is probably not their first language but the readability of the paper could be improved with some input from a skilled writer.
Specific comments on methods:
In the Data analysis and synthesis section it say that "RevMan5.3 software was employed for data analysis, with risk ratio (RR) and 95% C.I used for binary variables." But all analyses presented are in mean differences continuous measures and so there is no need for this sentence.
There was no mention of how the variance/Std.dev of change in mean difference is derived -is this calculated automatically in RevMan? I don't know if RevMan does this because I don't use this software -some description of how this is calculated (even if it is done automatically in RevMan) would be useful for people wanting to replicate their work.
VERSION 1 -AUTHOR RESPONSE
Responds to the reviewer's comments: According to patients with or without reduced ejection fraction, subgroup analyses were performed. Vitamin D supplementation was effective at reducing the LVEDD in patients with reduced ejection fraction (patients with reduced ejection fraction: heterogeneity χ2, P =0.07, I2 =62%；MD=-3.11mm, 95% CI: -5.67--0.55, P =0.02; patients without reduced ejection fraction: heterogeneity χ2, P =0.76, I2 =0%；MD=-0.91mm, 95% CI: -2.76-0.94, P =0.34) ( Figure 7 ). In addition, vitamin D supplementation was effective at increasing the LVEF in patients with reduced ejection fraction (patients with reduced ejection fraction: heterogeneity χ2, P =0.02, I2 =73%；MD=6.21%, 95% CI: 2.01-10.41, P =0.004; patients without reduced ejection fraction: heterogeneity χ2, P =0.002, I2 =80%；MD=2.74%, 95% CI: -1.96-7.45, P =0.25) (Figure 8 ). 4. Response to comment: (Conclusions have to be re-thought: every study ends with the statement "larger studies are needed"…. I think that the scope of this meta-analysis is to find new clues and address the design of future research. In fact it could be claimed that a larger study with an heavier end point already exist: EVITA trial (Zittermann et al. Eur Heart Journal 2017) included four hundred patient treated and followed for 3 years without finding any effect on mortality. If the message of your work is that this is not the end of the story (then you need to cite this work!!) you have to argue why and how larger studies will re open this issue. Ejection fraction is probably the best surrogate end point in heart failure patients, that's the reason why your paper deserves attention. According to this perspective please clarify if different selection criteria are needed (for example ejection fraction, vitamin D threshold, PTH threshold….) or if different vitamin D dosages would be superior, or if more echocardiographic parameter needs to be evaluated… ) Response: We thank the Prof. TURRINI for the constructive suggestions to improve this manuscript. We have re-written the limitation and conclusions. Although all trials included in this study are RCTs, there are still many limitations in this study: 1) because the current studies found that vitamin D has a weak and uncertain effect on ventricular remodelling and cardiac function in patients with HF and cannot improve exercise tolerance or reduce cardiac mortality, additional large-scale clinical studies are needed. Future research needs to focus on whether different vitamin D dosages would be superior; in addition, different selection criteria need to be defined (for example, ejection fraction, vitamin D threshold, PTH threshold, etc.) and additional echocardiographic parameters, the 6MWD and cardiovascular mortality need to be evaluated; 2) this study exhibits heterogeneity, and age stratification and whether there is reduced ejection fraction may be sources of clinical heterogeneity according to the subgroup analysis; 3) different recommended dosages of vitamin D are reported in different trials, which may affect study results; therefore, additional trials are required to explore the relationship between vitamin D dosage and effect; 4) the conclusions need to be interpreted with caution, as the extent of detected improvement in the remodelling parameters is close to the range of the inter-or intra-observer variability of the echocardiographic method itself. The baseline vitamin D level of patients and the follow-up duration may affect the study results, and except for Dalbeni et al [27] , whom have mentioned that no change in therapy was made during follow-up, other studies have not reported adjustments in HF medication. Therefore, whether the weak improvement in the remodelling parameters from vitamin D are attributed to other HF drugs is unclear.
In conclusion, this study shows that supplementation of vitamin D inhibit myocardial remodelling in patients with HF and improve their cardiac function. Vitamin D may be utilized as adjunctive HF medication for HF patients with an underlying lack of or insufficiency in vitamin D. This result is encouraging and of great clinical interest but still far from practical implications. The main implication is to encourage further research. EVITA trial studied the effect of vitamin D on all-cause mortality in HF. However, this study was not included because the data were not suitable for this study. Zittermann et al found that a daily vitamin D dose of 4,000IU did not reduce mortality in patients with advanced HF. However, it is worth noting that the primary endpoint was all-cause mortality and not cardiovascular mortality. This study mainly focused on the influence of vitamin D on ventricular remodelling and the ejection fraction. Even though these changes cannot reduce mortality in patients with HF, they may have other effects that improve the life quality and exercise tolerance of patients. We thank Prof. TURRINI for the positive comments of our work and the constructive suggestions to improve this manuscript. [26, 30, 45, 46] ; thus, our meta-analysis did not evaluate this parameter. There are probably many factors that affect exercise tolerance, such as physical condition, obesity, habits, and environment, and these confounding factors may obscure the weak force from the remodelled ventricle. 4. Response to comment: (I don't think this will be missed by the editorial review but the quality of English in this paper is not high. E.g. ) Response: We are very sorry for our incorrect writing and we have used the American Journal Experts (AJE) to proofread the manuscript. The certificate has been submitted as a supplementary file. (supplementary file 2) 5. Response to comment: (Specific comments on methods:
In the Data analysis and synthesis section it say that "RevMan5.3 software was employed for data analysis, with risk ratio (RR) and 95% C.I used for binary variables." But all analyses presented are in mean differences continuous measures and so there is no need for this sentence.)
Response: We are thankful to Prof. Oke for this comment. Following the Prof. Oke's suggestion, we have removed this sentence in manuscript. 6. Response to comment: (There was no mention of how the variance/Std.dev of change in mean difference is derived -is this calculated automatically in RevMan? I don't know if RevMan does this because I don't use this software -some description of how this is calculated (even if it is done automatically in RevMan) would be useful for people wanting to replicate their work.) Response: This is a good point, and we will be pleased to do some description considering the Prof. Oke's suggestion. According to the Cochrane Handbook，16.1.3 Missing standard deviations，16.1.3.2 Imputing standard deviations for changes from baseline: Note that the mean change in each group can always be obtained by subtracting the final mean from the baseline mean even if it is not presented explicitly. However, the information in this table does not allow us to calculate the standard deviation of the changes. We cannot know whether the changes were very consistent or very variable. Some other information in a paper may help us determine the standard deviation of the changes. If statistical analyses comparing the changes themselves are presented (e.g. confidence intervals, standard errors, t values, P values, F values) then the techniques described in Chapter 7 (Section 7.7.3) may be used. The specific methods have provided as a supplementary file. (supplementary file 3) When there is not enough information available to calculate the standard deviations for the changes, they can be imputed. When change-from-baseline standard deviations for the same outcome measure are available from other studies in the review, it may be reasonable to use these in place of the missing standard deviations.
The following alternative technique may be used for imputing missing standard deviations for changes from baseline (Follmann 1992 , Abrams 2005 . Here we describe (1) how to calculate the correlation coefficient from a study that is reported in considerable detail and (2) how to impute a change-frombaseline standard deviation in another study, making use of an imputed correlation coefficient. Note that the methods in (2) are applicable both to correlation coefficients obtained using (1) " These methods should be used sparingly, because one can never be sure that an imputed correlation is appropriate (correlations between baseline and final values will, for example, decrease with increasing time between baseline and final measurements, as well as depending on the outcomes and characteristics of the participants). An alternative to these methods is simply to use a comparison of final measurements, which in a randomized trial in theory estimates the same quantity as the comparison of changes from baseline." page 165
Can the authors add a comment in the results section, stating how many of the std deviations were fully reported in the original papers and whether they had to impute any, and what method was used if they were.
VERSION 2 -AUTHOR RESPONSE
Responds to the reviewer's comments: (1) Calculating a correlation coefficient from a study reported in considerable detail
Where either the baseline or final standard deviation is unavailable, then it may be substituted by the other, providing it is reasonable to assume that the intervention does not alter the variability of the outcome measure. Assuming the correlation coefficients from the two intervention groups are similar, a simple average will provide a reasonable measure of the similarity of baseline and final measurements across all individuals in the study.
(2) Imputing a change-from-baseline standard deviation using a correlation coefficient [28] were imputed by using the aforesaid formula (1). Corr（LVEF）=0.6/Corr (LVEDD) =0.8.
5. The standard deviations for changes from baseline were not reported in Turrini et al [26] .
6. The standard deviations for changes from baseline were not reported in Qu et al [31] .
7. The standard deviations for changes from baseline were not reported in Shedeed [29] The standard deviations for changes from baseline on the LVEF were reported in four studies [27, 28, 30, 32] . According to the Cochrane Handbook, the Corr were imputed by averaging the Corr of those four studies, and further imputed the standard deviations for changes from baseline for other studies [26, 31, 29] by using the aforesaid formula (2). The sensitivity analysis was conducted on condition that Corr =0.5, no changes were found in the conclusion.
The standard deviations for changes from baseline on the LVEDD were reported in three studies [27, 28, 30] . According to the Cochrane Handbook, the Corr were imputed by averaging the Corr of those three studies, and further imputed the standard deviations for changes from baseline for other studies [26, 29] by using the aforesaid formula (2). The sensitivity analysis was conducted on condition that Corr =0.5, 0.6, 0.8, no changes were found in the conclusion.
We add a comment in the results section:
The standard deviations for changes from baseline on the LVEF were reported in four studies [27, 28, 30, 32] . According to the Cochrane Handbook, the Corr were imputed by averaging the Corr of those four studies, and further imputed the standard deviations for changes from baseline for other studies [26, 31, 29] .
The standard deviations for changes from baseline on the LVEDD were reported in three studies [27, 28, 30] . According to the Cochrane Handbook, the Corr were imputed by averaging the Corr of those three studies, and further imputed the standard deviations for changes from baseline for other studies [26, 29] .
